Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption

被引:53
作者
Terciolo, Chloe [1 ,2 ]
Dapoigny, Michel [3 ]
Andre, Frederic [4 ,5 ]
机构
[1] Res Ctr Food Toxicol, INRA, UMR Toxalim 1331, F-31027 Toulouse, France
[2] Aix Marseille Univ, INSERM, UMR 911, CRO2, Marseille, France
[3] Univ Clermont Auvergne, Med Digest, CHU Estaing, CHU Clermont Ferrand,INSERM UMR 1107,Neurodol, Clermont Ferrand, France
[4] Aix Marseille Univ, CRCM, INSERM U1068, CNRS UMR 7258, Parc Sci & Technol Luminy, Marseille, France
[5] Inst Paoli Calmettes, Parc Sci & Technol Luminy, Marseille, France
来源
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY | 2019年 / 12卷
关键词
Saccharomyces boulardii CNCM I-745; apical junctional complex; leaky gut syndrome; intestinal barrier function; intestinal permeability; tight junctions; INFLAMMATORY-BOWEL-DISEASE; CLOSTRIDIUM-DIFFICILE TOXIN; GUT MICROBIOTA; ESCHERICHIA-COLI; EPITHELIAL BARRIER; ACUTE GASTROENTERITIS; JUNCTION PROTEINS; INDUCED MORTALITY; TIGHT JUNCTIONS; CHOLERA-TOXIN;
D O I
10.2147/CEG.S181590
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Intestinal barrier defects lead to "leaky gut syndrome", defined as an increase in intestinal permeability that allows the passage of luminal content into intestinal tissue and the bloodstream. Such a compromised intestinal barrier is the main factor underlying the pathogenesis of inflammatory bowel disease, but also commonly occurs in various systemic diseases such as viral infections and metabolic syndrome. The non-pathogenic yeast Saccharomyces boulardii CNCM I-745 has demonstrated its effectiveness as a probiotic in the prevention and treatment of antibiotic-associated, infectious and functional diarrhea. Via multiple mechanisms of action implicated in intestinal barrier function, S. boulardii has beneficial effects on altered intestinal microbiota and epithelial barrier defects in different pathologies. The well-studied probiotic yeast S. boulardii plays a crucial role in the preservation and/or restoration of intestinal barrier function in multiple disorders. This could be of major interest in diseases characterized by alterations in intestinal barrier function.
引用
收藏
页码:67 / 82
页数:16
相关论文
共 139 条
  • [1] Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial
    Abbas, Zaigham
    Yakoob, Javed
    Jafri, Wasim
    Ahmad, Zubair
    Azam, Zahid
    Usman, Muhammad W.
    Shamim, Sara
    Islam, Muhammad
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 26 (06) : 630 - 639
  • [2] Low diversity of the gut microbiota in infants with atopic eczema
    Abrahamsson, Thomas R.
    Jakobsson, Hedvig E.
    Andersson, Anders F.
    Bjorksten, Bengt
    Engstrand, Lars
    Jenmalm, Maria C.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : 434 - U244
  • [3] Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics
    Ajslev, T. A.
    Andersen, C. S.
    Gamborg, M.
    Sorensen, T. I. A.
    Jess, T.
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2011, 35 (04) : 522 - 529
  • [4] Interleukin-6 Modulation of Intestinal Epithelial Tight Junction Permeability Is Mediated by JNK Pathway Activation of Claudin-2 Gene
    Al-Sadi, Rana
    Ye, Dongmei
    Boivin, Michel
    Guo, Shuhong
    Hashimi, Mariam
    Ereifej, Lisa
    Ma, Thomas Y.
    [J]. PLOS ONE, 2014, 9 (03):
  • [5] Awad WA, 2017, TOXINS, V9, pE60, DOI DOI 10.3390/T0XINS
  • [6] Association of Antibiotics in Infancy With Early Childhood Obesity
    Bailey, L. Charles
    Forrest, Christopher B.
    Zhang, Peixin
    Richards, Thomas M.
    Livshits, Alice
    DeRusso, Patricia A.
    [J]. JAMA PEDIATRICS, 2014, 168 (11) : 1063 - 1069
  • [7] Gastroenterology 2 - Inflammatory bowel disease: clinical aspects and established and evolving therapies
    Baumgart, Daniel C.
    Sandborn, William J.
    [J]. LANCET, 2007, 369 (9573) : 1641 - 1657
  • [8] Antibiotic-associated diarrhoea and Clostridium difficile in the community
    Beaugerie, L
    Flahault, A
    Barbut, F
    Atlan, P
    Lalande, V
    Cousin, P
    Cadilhac, M
    Petit, JC
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (07) : 905 - 912
  • [9] Berding K, 2018, FRONTIERS NEUROSCIEN, P12
  • [10] Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation
    Berkes, J
    Viswanathan, VK
    Savkovic, SD
    Hecht, G
    [J]. GUT, 2003, 52 (03) : 439 - 451